Jazz First Patient Enrolled in P-III (IMforte) Trial of Zepzelca (lurbinectedin) + Tecentriq for Extensive-Stage Small Cell Lung Cancer
Shots:
- The first patient has enrolled in a P-III (IMforte) trial to evaluate the efficacy, safety, and PK of Zepzelca + Tecentriq (PD-L1 inhibitor) vs SoC in patients with es-SCLC, following induction therapy with carboplatin, etoposide, and atezolizumab. The trial is being conducted in collaboration with F. Hoffmann-La Roche
- The primary objective is to determine the ability to improve outcomes for patients with ES-SCLC, compared with SoC as measured by PFS and OS
- Additionally, the trial will support the sNDA for Zepzelca + Tecentriq as a 1L maintenance treatment of ES-SCLC. Zepzelca is an alkylating drug that binds guanine residues within DNA
Ref: PR Newswire | Image: Jazz
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com